Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Terminated 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 11Neoplasm Metastasis 2Colonic Neoplasms 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Inflammatory Breast Neoplasms 1Gastrointestinal Neoplasms 1Erythema 1Edema 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Gemcitabine 42130-nm albumin-bound paclitaxel 26Albumin-Bound Paclitaxel 18Irinotecan 16Oxaliplatin 14Fluorouracil 14pembrolizumab 13Nivolumab 13Magnetic Resonance Spectroscopy 11Leucovorin 11Taxes 10Specimen Handling 9Biopsy 9Cisplatin 8Capecitabine 7folfirinox 6Radiotherapy 6Carboplatin 6irinotecan sucrosofate 5durvalumab 5Ipilimumab 5Cyclophosphamide 5olaparib 4defactinib 4Surveys and Questionnaires 4Standard of Care 4Radiosurgery 4Immunoglobulin G 4Disulfides 4dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pancreatic Neoplasms × Panitumumab × Clear all
NCT05121038 2024-12-17

CENDIFOX

University of Kansas Medical Center

Phase 1/2 Active not recruiting
50 enrolled
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡